bluebird bio

Latest Headlines

Latest Headlines

The top 10 biotech IPOs of 2013

Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...

UPDATED: Fresh burst of biotech IPO pitches launches a busy Q4 season

After a slight lull in the biotech IPO arena, new offerings came barreling back this week with some fresh breakouts. In particular Foundation Medicine priced over the range and immediately soared more than 80%. And Ophthotech also crested its range, erasing any lingering doubts about the short-term sustainability of the biotech IPO frenzy. Together they raised $273 million in a 24-hour pop. Read the report >>

Fate IPO flop raises fresh concerns about investors' appetite for biotech

A funny thing happened to Fate Therapeutics on its way to the hot biotech IPO market. Following fast on the heels on a pair of breakout IPOs, the offering flopped. And the setback is reigniting a debate over just how long the IPO market can continue to sizzle.

The biotech IPO scene turns red hot

During all of last year there were only 11 biotech IPOs. But even that weak number looked pretty good compared to the barren years leading away from the 2008 financial crisis. In the last 6 months, though, the industry has seen a tremendous rebound, with almost twice that number of IPOs in half the time. And there's no sign that the great leap into the public market is waning, with 10 more IPOs in the queue. Read the full report >>

UPDATED: Bluebird IPO busts out, raises $101M as biotech offerings turn red hot

Biotech IPOs are officially back in vogue. Bluebird bio--set up to develop new gene therapies for orphan diseases--priced its IPO at $17 a share, actually above its range. The biotech raised $101 million after bumping up the number of shares it had on offer.

UPDATED: PTC, Esperion, bluebird join the IPO frenzy in biotech with genetic therapies

Two more biotech outfits emerged this week as contenders to complete initial public offerings, highlighting the open season for the deals this year. Bluebird bio and PTC Therapeutics has mounted campaigns to go public with pipelines that target the molecular causes of rare genetic diseases.

UPDATED: Celgene makes big splash in gene therapy with two key cancer collaborations

Celgene has made a move into the resurgent gene therapy field. With a focus on immunotherapies against cancer, Celgene revealed collaborations with a pair of partners on Thursday that highlights increased industry interest in the previously shunned gene therapy field after a series of regulatory and scientific victories in recent years.

ViaCyte, Bluebird score $19.4M in CA stem cell funds for game-changing therapies

California has steered nearly $20 million in stem cell awards to a pair of biotech companies working on potentially revolutionary treatments for diabetes and the blood disorder beta-thalassemia.

Defining 'fierce' in the modern age of drug and device development

Now, more than ever, the life sciences industry is all about innovative and disruptive technologies. Every year for the past decade, FierceBiotech has made its picks on which companies hold the best odds for success in our Fierce 15 report. This year, though, we've added another Fierce 15 to focus on medical devices and diagnostics. I'd like to encourage readers to consider the differences by comparing the companies in each report.

FierceBiotech's 2012 Fierce 15 at BioPharm America

Nick Leschly, the CEO of Bluebird Bio, playfully dubbed the ambitious spirit of biotechs Levin Syndrome, a fictional affliction named after Third Rock Ventures' Mark Levin that compels biotech entrepreneurs to, as they say, go big or go home. Our Fierce 15 companies are all "going big." They also went home… with trophies. Check out the slideshow below.